Clinical characteristics and prognostic factors of prostate cancer with liver metastases
- 20 August 2013
- journal article
- research article
- Published by Springer Nature in Tumor Biology
- Vol. 35 (1) , 595-601
Abstract
Liver metastasis from prostate cancer is uncommon and remains poorly understood. We computer searched the clinical records of all our patients registered into a database to identify patients that presented or developed liver metastases. A total of 27 prostate cancer patients with ultrasound or CT/MR imaging evidence of liver metastases were included in our analysis. The liver metastasis rate from metastatic prostate cancer was 4.29 %. Eight (29.63 %) patients had previously untreated, hormone-naive prostate cancer (synchronous liver metastases at diagnosis of prostate cancer), whereas 19 (70.37 %) patients had already been diagnosed as having hormone-refractory prostate cancer. In the hormone-naive group, the median overall survival after liver metastases diagnosis was 38 months and half of the patients were still alive at the latest follow-up, whereas only 6 months in the hormone-refractory group (p = 0.003). High concentration of serum neuron-specific enolase and previous chemotherapy were associated with a significantly poor overall survival after liver metastases in the hormone-refractory group using Kaplan–Meier curves and logrank tests for univariate analysis.Keywords
This publication has 15 references indexed in Scilit:
- Partial response of liver metastases treated with abiraterone in castration-resistant prostate cancer: A case reportOncology Letters, 2013
- Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?Annals of Oncology, 2012
- Prostate cancer in the senior men from rural areas in east district of China: Contemporary management and 5-year outcomes at multi-institutional collaborationCancer Letters, 2012
- Central nervous system metastases from castration-resistant prostate cancer in the docetaxel eraJournal of Neuro-Oncology, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- L’épidémiologie des cancers en France en 2010 : comparaison avec les États-UnisBulletin du Cancer, 2010
- Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975Annals of Oncology, 2009
- Liver metastases in prostate carcinoma: clinical characteristics and outcomeBJU International, 2006
- Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory diseaseEndocrine-Related Cancer, 2005
- Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate CancerNew England Journal of Medicine, 1998